The Europe against immature lung (EURAIL) project. Strategies for the prevention and treatment of lung immaturity in neonates;Proyecto EURAIL. Estrategias de prevención y tratamiento contra la inmadurez pulmonar en españa

Anales de Pediatria

Volumn 58, Issue 1, 2003, Pages 45-51

  Valls i Soler, A ^a,b   Paramo Andres S ^a   Fernandez Ruanova B ^a   Morcillo Sopena, F ^b   Monleon Alegre F J ^b   Carretero Diaz V ^c   Marin Herrero J ^c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

Corticosteroids; Immature lung; Neonatal respiratory distress syndrome; Prenatal care; Surfactant

Indexed keywords

STEROID; SURFACTANT;

ARTICLE; ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; DRUG EXPOSURE; DRUG INDICATION; EUROPE; FETUS LUNG MATURITY; HUMAN; INTUBATION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NEWBORN MORBIDITY; POSITIVE END EXPIRATORY PRESSURE; POSTNATAL CARE; PRENATAL CARE; QUESTIONNAIRE; SPAIN; VERY LOW BIRTH WEIGHT;

EID: 0037494952     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042248     Document Type: Article

References (44)

1. Bakketeig LS, Bergsjo P. The epidemiology of preterm birth. En: Kurjak A, editor. Textbook of Perinatal Medicine. London: Parthenon Publ Group, 1998; p. 1331-6.
2. Avery ME, Meade J, Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:517-23.
3. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of respiratory distress syndrome in premature infants. Pediatrics 1972;50:515-25.
4. Fujiwara T, Chida S, Watabe YJ, Meata H, Morita T, Abe T. Artificial surfactant therapy. Lancet 1980;1:5-9.
5. Crowley P, Chalmers I, Keirse MJNC, Chalmers I, Keirse M, The effects of corticosteroid administration before preterm delivery: An overview of the evidence from controlled trials. Br J Obstet Gynecol 1990;97:11-25.
6. INH Consensus Developmental Panel on the effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1996;273:413-8.
7. Empana JP, Anceschi MM, Visser GHA, Szabó I, Breart G. Use of antenatal corticosteroids in Europe. Prenat Neonat Med 2001;6(Suppl 6):1-7.
8. Colaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: An international randomized clinical trial. Pediatrics 1988;82:683-9.
9. Bevilacqua G, Halliday HL, Parmigiani S, Robertson B, Monici-Petri P, Tubman R, et al. Randomized multicentre trial of treatment with porcine natural surfactant for moderately severe neonatal respiratory distress syndrome. J Perinat Med 1993;21:329-40.
10. Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC, Multicentre randomized trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 1995;69:276-8.
11. Halliday H. Overview of clinical trials comparing natural and synthetic surfactants. Biology Neonate 1995;67(Suppl 1):32-47.
12. Jobe A, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 1993;168:508-13.
13. Kari MA, Hallman M, Eronen M, Teramo K, Virtanen M, Kaivisto M, et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: A randomized placebo controlled multicentre study. Pediatrics 1994;93:730-6.
14. Cosmi EV, Breart G, Halliday HL, Saugstad OD, Szabó I, Visser GHA. Antenatal and postnatal management of fetal lung immaturity in Europe. Report of EURAIL (Europe Against Immature Lung). Prenat Neonat Med 2001;6(Suppl 6):1-88.
15. Derom R, Orlebeke J, Erikson A. The epidemiology of multple births. En: Kurjak A, editor. Textbook of Perinatal Medicine. London: Parthenon Publ Group, 1998; p. 1463-80.
16. Anceschi MM, Antsaklis A, Kurjak A, Pal A, Pereira Leite L. Beneficial effects of antepartum corticosteroids. Prenat Neonat Med 2001;6:31-41.
17. Visser GHA, Csermely T, Casmi EV. Side-effects of prenatal steroids. Prenat Neonat Med 2001;6:42-9.
18. Truffert P, Breart G, Goelz R, Saugstad OD, Halliday HL, Bevilaqua G. Treatment strategies in Europe for neonatal pulmonary morbidity using surfactant and postnatal corticosteroids. Prenat Neonat Med 2001;6(Suppl 6):8-14.
19. Visser GHA, Anceschi MM. Guidelines on antepartum corticosteroids. Prenat Neonat Med 2001;6:78-80.
20. Quilivan JA, Evans SF, Dunlop SA, Beazley LD, Newnham JP. Use of corticosteroids by Australian obstetricians - a survery of clinical practice. Aust N Z J Obstet Gynaecol 1998;38:1-7.
21. Brocklehurst P, Gates S, Mckenzie-McHarg K, Alfirevic Z, Chamberlain G. Are we prescribing multiple courses of antenatal corticosteroids? A survey of practice in the U.K. Br J Obstet Gynaecol 1999;106:977-9.
22. Dammann O, Matthews SG. Repeated Antenatal Glucocorticoid Exposure and the Developing Brain. Pediatr Res 2001;50:563-4.
23. Guinn DA, Atkinson MW, Sullivan L, Lee MJ, MacGregor S, Parilla BV, et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery. A randomized controlled trial. JAMA 2001;286:1581-7.
24. Bolt RJ, Weissenbruch MM, Lafeber HN, Delemarre-van de Waal HA. Glucocorticoids and Lung Development in the Fetus and Preterm Infant. P Pulmonol 2001;32:76-91.
25. Modi N, Lewis H, Al-Naqeeb N, Ajayi-Obe M, Doré CJ, Rutherford M. The Effects of Repeated Antenatal Glucocorticoid Therapy on the Developing Brain. Pediatr Res 2001;50:581-5.
26. Edwards HE, Burnham WM. The Developing Nervous System: A series of Review Articles. Pediatr Res 2001;50:433-40.
27. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: Role of preservaties. Pediatr Res 2001;50:706-11.
28. Van Marten LJ, Allered EN, Levinton A, Pagano M, Parad R, Moore M, and the Neonatology Committee for The Development Epidemiology Network. Antenatal glucocorticoid does not reduce chronic lung disease among surviving preterm infants. J Pediatr 2001;138:198-204.
29. Silver RK, Vyskocil C, Solomon SL, Ragin A, Neerhof MG, Farell EE. Randomized Trial of Antenatal Dexamethasone in Surfactant-Treated Infants Delivered Before 30 Weeks' Gestation. Obstet Gynecol 1996;87:638-91.
30. Valls i Soler A, Paramo S, of behalf of the Spanish Surfactant Collaborative Study Group. Prenatal steroids do not modify surfactant needs after prophylaxis in infants 28-30 weeks. Pediatr Res 2001; p. 49.
31. Saugtad OD, Bevilacqua G, Katona M, Speer CP, Valls i Soler A. Surfactant therapy in the newborn. Prenat Neonat Med 2001;6:56-9.
32. Navas Serrano VM, Cuevas García MA, Vila Alvarez JA, Martínez Fernández V, Morcillo Sopena F, Valls i Soler A. Profilaxis y tratamiento del síndrome de distrés respiratorio con diferentes surfactantes. An Esp Pecliatr 2002;56:40-4.
33. Phibbs CS, Phibbs RH, Wakeley A, Schlueter MA, Sniderman S, Tooley WH. Cost effects of surfactant therapy for neonatal respiratory distress. J Pediatr 1993;123:953-62.
34. Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F. Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997;100:E1/E4.
35. Walti H, Paris-Llado J, Breart G, Couchard M. Porcine surfactant replacement therapy in newborns of 25-31 weeks'gestation: A randomized, multicentre trial of prophylaxis versus rescue with multiple low does. The French Collaborative Multicentre Study Group. Acta Paediatr 1995;84:913-21.
36. Halliday HL. Clinical trials of postnatal corticosteroids: Inhaled and systemic. Biol Neonate 1999;76(Suppl 1):29-40.
37. Halliday HL. Benefits and side-effects of steroids in neonatal medicine. Prenat Neonat Med 2001;6:50-5.
38. Jobe AH. Glucocorticoids in Perinatal medicine: Misguided rockets? J Pediatr 2000;137:1-3.
39. Finer NN, Craft A, Vaucher YE, Clark RH, Sola A. Postnatal steroids: Short-term gain, long-tern pain? J Pediatr 2000;137:9-13.
40. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer D, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000;83:F177-F181.
41. The Vermont Oxford Network Steroid Study Group. Early Postnatal dexamethasone Therapy for the Prevention of Chronic Lung Disease. Pediatrics 2001;108:741-8.
42. Valls i Soler A, Sulyok E, Gastiasoro E, Alvarez FJ, Lachmann B. New developments in neonatal respiratory treatment: From conventional to liquid ventilation. Prenat Neonat Med 2001;6:66-74.
43. Bevilacqua G, Goelz R, Halliday HL. Guidelines on surfactant treatment. Prenat Neonat Med 2001;6:84-8.
44. Halliday HL. Guidelines on neonatal steroids. Prenat Neonat Med 2001;6:81-3.